Medicine & Pharmaceuticals News
RovithoMed Expands Coordinated Medical Tourism Services for International Patients
RovithoMed , an Istanbul-based medical tourism company, is expanding its coordinated approach to healthcare travel, bringing access to multiple medical disciplines and patient support services together for people considering treatment in Turkey. The company’s network covers dental care, hair restoration, dermatology, facial aesthetics, oculoplastic procedures and plastic aesthetic treatments. RovithoMed also coordinates practical elements of international healthcare travel, including initial consultations, treatment planning, accommodation assistance, airport and local transfers, and post-treatment communication. The approach is intended to give international patients a central point of coordination rather than requiring them to arrange each part of a medical trip independently. “International patients have to consider much more than the procedure itself,” said Mehmet Ebcim, Founder of RovithoMed. “They want to understand who will treat them, how their treatment will be organised and who they can communicate with before and after travelling. Our aim is to bring those elements together in a clearer and more coordinated process.” A Multidisciplinary Network Supporting International Patient Care The RovithoMed network brings together practitioners working across several areas of medical and aesthetic care. Among them is Dr Yıldız Acar Ebcim , MD, FEBO, an ophthalmologist whose practice includes oculoplastic procedures involving the eyelids and surrounding facial area. Procedures coordinated through the network include lower blepharoplasty , subject to individual consultation and assessment by the relevant medical practitioner. The network also includes dermatologist Associate Professor Tuğba Falay Gür, MD, and ENT specialist Halim İş, MD. Dental services are supported by Dt. Saliha Ezgi Akıncı, whose work includes restorative, aesthetic and implant-based dental treatment planning. By bringing different disciplines into the same network, RovithoMed aims to simplify the organisational side of treatment for patients travelling internationally, with individual treatment decisions subject to consultation with the appropriate healthcare professional. Coordinating Treatment Planning and the Wider Medical Travel Process Travelling internationally for healthcare can involve a series of medical and practical decisions. Patients may need to identify an appropriate practitioner, arrange consultations and treatment dates, organise travel and accommodation, and maintain communication after returning home. RovithoMed’s model is designed to coordinate these stages through a single point of contact. Patients can begin remotely by providing relevant information and outlining the treatment they are considering. RovithoMed can then coordinate consultations with appropriate practitioners before travel. Once a treatment plan has been determined by the relevant healthcare professionals, the company can assist with arrangements surrounding the visit, including appointments, accommodation and transfers. The model reflects a wider focus in Turkey on international health services and the experience of patients travelling for treatment. “We have brought dental care, hair treatments, facial aesthetics, dermatology and plastic aesthetic procedures together within one coordinated network,” Ebcim said. “The objective is to make the organisational side of the experience more transparent and manageable for international patients.” RovithoMed said its focus is on developing this coordinated model while maintaining communication between patients, practitioners and supporting services throughout the healthcare travel process.
Ace Therapeutics Expands End-to-End CRO Capabilities with Fully Customizable Respiratory Infection Model Development Platform
Streamlining Proteomic Sample Preparation, Amerigo Scientific Unveils Its Full Suite of Mass Spectrometry Grade Enzymes
Chronic Lyme Disease & Infertility: Customized Family Treatment Plans Announced
- August 12, 2026Medicine & Pharmaceuticals
Regenics Launches Physician-Led GLP-1 Membership Program With Lower Medication Pricing
Regenics has launched a new physician-led GLP-1 membership program designed to expand access to medical weight loss care through ongoing clinical oversight and lower medication pricing. The new model replaces simplified bundled programs with a membership structure intended to support continuous supervision by the Regenics medical team. Under the program, patients receive unlimited access to their care team, along with ongoing prescription management, dose adjustments when appropriate, and refill coordination, with treatment plans tailored over time based on physiology, biomarker trends, and long-term health goals. Photo Courtesy of: Regenics Membership starts at $39 for the first month and $79 per month thereafter, providing access to Regenics' physician-led weight management framework. GLP-1 medications are billed separately based on prescribed dose, allowing pricing to change as treatment progresses in line with each patient's clinical needs. Regenics offers semaglutide starting at $119 and tirzepatide starting at $199, with dosing determined by each patient's metabolic response and physician guidance. The program builds on Regenics' physician-led care model, which began at its Los Angeles-area clinic and later expanded through telemedicine to serve patients across the United States. Medical consultations at Regenics continue to be conducted by licensed medical professionals as the company broadens access to supervised GLP-1 treatment. "Biomarkers are the map. Your symptoms are the story. Our job is to bring those two things together," said Phillip Marks, Head Nurse Practitioner at Regenics. In addition to GLP-1 care, members may also access physician-guided therapies such as pharmaceutical-grade peptide protocols, hormone optimization programs, metabolic support treatments, and advanced biomarker testing. The program's weight management care is built around semaglutide and tirzepatide—FDA-approved active ingredients used in leading prescription weight-loss medications, including GLP-1 and dual GIP/GLP-1 therapies. Regenics now includes complimentary medication delivery so prescribed therapies can be shipped directly to patients' homes without added shipping costs. "Patients want more than access to medication," said Elise Easom, COO at Regenics. "They want physician guidance, ongoing support, and care that can adapt as their body and goals change. This membership model allows us to deliver that level of clinical support while improving affordability." Regenics said the membership launch reflects its broader view that medical weight loss should be managed as an ongoing clinical process rather than a one-time transaction. The company noted that more information on the GLP-1 membership structure, pricing, and eligibility criteria is available through its dedicated membership page at regenics.com/membership-landing. About Regenics Regenics is a health and hormone optimization clinic built around physician-led, patient-centered care. The clinic helps individuals improve energy, metabolic function, weight control, sexual health, and long-term health through evidence-based medical protocols and personalized plans grounded in physiology and clinical data. What began as a local practice in Tarzana, California, has grown into one of the fastest-growing clinics in its field, expanding from in-person care in the Los Angeles area to secure telemedicine that now serves patients across the United States, with patient care remaining the constant behind that growth.
- July 30, 2026Medicine & Pharmaceuticals
Dr. Milisha Chotai Receives 2026 Global Recognition Award For Clinically Driven Preventive Dental Innovation
Dr. Milisha Chotai has been honored with a 2026 Global Recognition Award for Smile Boosters™, a dissolvable supplement designed for use between brushing. The award recognizes her evidence-based response to persistent gaps in everyday oral health care and its alignment with modern lifestyles. Photo Courtesy of Milisha Chotai Dr. Chotai received the award in the innovation and startup of the year category for advancing a structured approach to preventive dental care. Drawing on more than two decades of clinical experience, she identified a critical gap in traditional oral hygiene guidance: the extended periods between brushings, during which teeth are repeatedly exposed to food, drink, and environmental factors. Smile Boosters™ was developed as a practical, chairside-informed solution that integrates seamlessly into daily routines without requiring disruption or access to a sink. Her work reflects a broader shift in preventive care, where effectiveness is increasingly measured by how well solutions fit into contemporary habits shaped by frequent snacking, varied diets, and demanding schedules. Clinical Foundations And Professional Path Dr. Chotai’s career combines clinical practice, leadership, and education. As owner and principal dental surgeon at Newnham Dental Practice in Cambridgeshire, she oversees multidisciplinary teams and manages complex restorative and implant cases. Her role requires consistent attention to clinical outcomes, operational processes, and team development. She also contributes to academic advancement as a past honorary lecturer in dental implantology at the University of Bristol, reinforcing her commitment to evidence-based practice and knowledge sharing. Her academic credentials include an MSc in Dental Implantology and an MSc in Medical Education, as well as business certifications from Harvard Business School Online. This combination allows her to bridge clinical rigor with practical implementation, ensuring innovations like Smile Boosters™ are both scientifically grounded and viable in real-world settings. Extensive patient interactions, case studies, and clinical observations shaped the product’s development. Dr. Chotai identified a recurring pattern: patients who adhered to standard brushing advice still experienced preventable issues. By reframing the “between brushing” period as central rather than incidental, she positioned oral supplements as a meaningful extension of daily care. Innovation In Everyday Oral Care Traditional oral care models focus heavily on brushing moments, often overlooking the continuous exposure teeth face throughout the day. Dr. Chotai addressed this limitation by developing a dissolvable supplement that delivers fluoride and xylitol in a convenient, on-the-go format. Designed with patient behavior in mind, Smile Boosters™ enhances existing habits rather than requiring new ones. This approach aligns with growing 2026 industry trends favoring preventive solutions that integrate effortlessly into daily life, improving adherence and long-term outcomes. “Preventive strategies need to reflect how people live now, where time and environment influence consistency more than intention,” Dr. Chotai noted, highlighting the practical foundation behind the product. Global Recognition Awards judges evaluated her submission using criteria such as novelty, market impact, and ability to address global challenges. Her entry achieved top scores across innovation categories. The organization applies the Rasch model to convert evaluations into a standardized measurement scale, enabling consistent comparisons across industries. Final Words “Dr. Milisha Chotai’s work demonstrates how careful clinical insight can inform practical solutions that fit into everyday life,” said Alex Sterling, spokesperson for Global Recognition Awards. Her recognition underscores the importance of translating clinical expertise into accessible tools that improve patient outcomes. By focusing on the often-overlooked hours between brushing, Chotai has helped reshape preventive care frameworks while maintaining a strong foundation in established science. “The ability to connect rigorous clinical practice with accessible, everyday solutions is exactly what this award seeks to recognize,” Sterling added. Dr. Chotai’s journey from clinician to innovator remains rooted in prevention, addressing oral health issues before they become irreversible. Smile Boosters™ encourages both professionals and patients to consider the full daily cycle of oral care, supporting a shift toward more realistic and effective preventive strategies. About Global Recognition Awards Global Recognition Awards is an international organization that honors individuals and companies making meaningful contributions to their industries. Its evaluation framework emphasizes measurable impact, sustained commitment, and the potential to influence broader practices across sectors.
- July 29, 2026Medicine & Pharmaceuticals
New: Survival Skills for Women’s Health Fall 2026 - Experts Teach Menopause
Physicians, nurse practitioners, physician assistants, nurses, and allied healthcare providers in clinical practice looking for the latest information on healthcare of midlife women in perimenopause, menopause and beyond, can register to attend Survival Skills for Women’s Health - Experts Teach Menopause scheduled for November 6-8, 2026. World Class CME is sponsoring this year's event, which will cover key issues such as: Menopausal Hormone Therapy in Breast Cancer Survivors - Explainining the core physiology/pathophysiology of breast cancer (BC), and mechanisms relevant to the use of both local and systemic menopausal hormone therapy (MHT) following primary BC treatment. Understanding selected outcomes from major clinical trials, observational data, and guidelines, emphasizing their strengths/limitations relating to the use of MHT in BC survivors. Distinguishing relative vs absolute risk/benefit (short-term vs long-term) to support accurate clinical interpretation/utilization of MHT in this setting. Translating the data presented into patient selection, counseling, and shared decision-making for prescribing MHT in this setting. Menopausal Hormone Therapy: Where Does the Pendulum Belong - Faculty: James A. Simon, MD - A practical, evidence-based update on menopausal hormone therapy (MHT). The session examines current risk-benefit data, patient selection, timing, regimens, and how clinicians should position MHT in 2026 after two decades of shifting guidance following the Women’s Health Initiative. Testosterone: Myths and Realities - Faculty: James A. Simon, MD - A clear-eyed review of testosterone use in midlife women. Covers evidence for libido, energy, and body composition; common misconceptions; appropriate candidates; dosing and monitoring; and what the data do (and do not) support. Genitourinary Syndrome of Menopause: Yes, Dyspareunia, but Much More - Faculty: Alyse Kelly-Jones, MD - A comprehensive look at GSM beyond painful intercourse. Addresses diagnosis, the full spectrum of genitourinary symptoms, impact on quality of life, and evidence-based hormonal and non-hormonal treatment strategies that generalists can implement immediately. Full details on the event can be found on the company website at https://worldclasscme.com/events/survival-skills-for-womens-health-fall/ . When asked about the reasons behind creating this event, the host of the event, World Class CME said: "It was so great to hear from smart people who were presenting the results of their curiosity and engagement with the information. I felt so energized by the depth of exploration of theory and data." - Meghan Bride, WHNP-BC The World Class CME website has full details about the sessions at this year's event. Interested parties can visit the website at: https://worldclasscme.com/events/survival-skills-for-womens-health-fall/ .
- July 29, 2026Medicine & Pharmaceuticals
Novadose & Pure Pharmaceuticals Driving the Future of Peptide Science
As demand for pharmaceutical-grade peptides continues to accelerate worldwide, two companies are making a significant investment in what they believe will become the industry’s most valuable currency trust. The global peptide industry is experiencing unprecedented growth. As scientific research advances and manufacturing capabilities evolve, expectations surrounding product quality, traceability and regulatory compliance are rising just as rapidly. Against this backdrop, Novadose and Pure Pharmaceutical have announced a strategic partnership aimed at redefining standards across peptide manufacturing and supply-chain transparency. While financial details remain undisclosed, the companies confirm they are making a substantial long-term investment into next-generation peptide manufacturing, advanced quality systems and research-driven process development. The objective is clear: to deliver consistently high-purity peptides supported by comprehensive quality assurance and documented traceability throughout every stage of production. Industry observers note that the peptide sector is entering a period where manufacturing excellence is becoming just as important as scientific innovation. Increasingly, customers and partners want more than certificates of analysis. They expect confidence that every stage of production—from raw materials and analytical testing to logistics and final delivery—has been managed to the highest possible standard. According to representatives from the partnership, this philosophy has become the foundation of the collaboration. “Transparency should never begin with the finished product. It should begin at inception and continue throughout manufacturing, quality assurance, logistics and delivery.” Pure Pharmaceutical will contribute pharmaceutical-quality manufacturing processes, stringent quality management systems and end-to-end production traceability. Novadose will focus on delivering that manufacturing excellence through a customer-first approach built around reliability, consistency and confidence. The announcement comes at a time when expectations across the life sciences sector continue to evolve. As quality requirements become increasingly rigorous, manufacturers capable of demonstrating—not simply claiming—operational excellence are expected to distinguish themselves in an increasingly competitive market. Rather than competing on volume alone, Novadose and Pure Pharmaceutical say their long-term strategy is centred on scientific investment, manufacturing precision and complete transparency throughout the supply chain. Whether this approach will influence broader industry standards remains to be seen, but one message is already clear: the conversation surrounding peptide manufacturing is changing. In the years ahead, success may depend less on who can manufacture the most—and more on who can demonstrate the highest standards of quality, accountability and trust. Novadose × Pure Pharmaceutical Raising the Standard. From Inception
- July 29, 2026Medicine & Pharmaceuticals
Most Utah Deaths Never Reach the State Medical Examiner. Postmortem Pathology Offers Salt Lake City Families a Private Autopsy Option.
Roughly two out of every three deaths in Utah never come under the authority of the state Office of the Medical Examiner, which leaves thousands of families each year without a public route to a postmortem examination. Postmortem Pathology, a nationwide practice offering private autopsy services in Salt Lake City and across the Wasatch Front, exists to close that gap. State medical examiner authority in Utah reaches only a fraction of deaths, somewhere near one in three. The office logged 7,899 death investigations over the course of 2023. Its mandate covers deaths that arrive without warning, involve violence, or carry circumstances no physician can readily explain. Even inside that mandate, a full autopsy is not automatic. What remains is a large category of Utah families standing outside the system altogether. A parent dies in an assisted living facility. A relative is certified as a natural death while the family suspects a diagnosis was missed. A sudden cardiac death raises the question of whether surviving children carry the same inherited risk. In each case, a private autopsy in Salt Lake City is frequently the only way forward. "Families come to us because the question they are asking is not the question the state system is built to answer," said Dr. Dan Lingamfelter, lead pathologist at Postmortem Pathology. "A death can be entirely expected from a legal standpoint and still leave a family with no idea what actually happened medically. That gap is where we work." Timing matters as much as access. For families working against probate deadlines, insurance filing windows, or civil claims governed by fixed limitation periods, an independent autopsy in Salt Lake City can be booked directly and delivered on an agreed schedule. Record access is a third consideration. Utah statute shields medical examiner files from open release. Attorneys who want them must first establish standing, ordinarily through written authorization from the legal next of kin, appointment by a court as representative of the estate, or a subpoena or order issued by a judge. An examination commissioned privately produces a report that belongs to the family or their counsel from day one. Postmortem Pathology is run by pathologists holding board certification in anatomic, clinical, and forensic pathology, with case experience spanning criminal and civil proceedings. A standard examination covers inspection of the body inside and out, screening for drugs and toxins, and microscopic study of tissue. Pricing opens at $5,000. Findings stay confidential and are released only to the family or the parties they designate. Families and attorneys pursuing a private autopsy in Salt Lake City can contact Postmortem Pathology directly to review case specifics, scheduling, and coordination with whichever funeral home or facility currently holds the decedent. About Postmortem Pathology Postmortem Pathology is a private autopsy and forensic pathology practice staffed by pathologist’s board certified in anatomic, clinical, and forensic pathology. The firm handles cases in all 50 states, including private autopsy services in Salt Lake City and throughout Utah, working with families, attorneys, insurers, and treating physicians. More information is available at postmortempath.com.
- July 24, 2026Medicine & Pharmaceuticals
Ace Therapeutics Introduces Validated Custom Animal Models to Support Cardiac Ischemia-Reperfusion Research
Global preclinical CRO Ace Therapeutics expands its cardiovascular disease model portfolio with fully validated myocardial ischemia-reperfusion (MI/R) animal modeling services, equipping academic labs and biopharma developers with reproducible research tools to advance ischemic cardiomyopathy therapeutic discovery. Surgical coronary artery ligation remains the gold-standard method to recapitulate human heart attack and reperfusion therapy pathology. Ace Therapeutics optimizes every procedural step for consistent, customizable model generation. Under deep anesthesia, Ace Therapeutics’ experts perform thoracotomy, temporary ligation of the left anterior descending coronary artery, timed ischemia incubation, suture release for reperfusion, followed by chest closure and layered skin closure. Post-operative continuous animal monitoring mitigates infection, organ failure, and premature mortality, ensuring intact study cohorts for long-term efficacy and mechanistic readouts. The custom coronary artery ligation MI/R models cover a broad panel of validated animal strains to match diverse research design requirements, including C57BL/6 and BALB/c mice, SD and Wistar rats, alongside New Zealand white and Japanese white rabbits. Rigorous multi-layered model validation protocols guarantee a reliable ischemic injury phenotype: real-time intraoperative ECG monitoring tracks ST-segment elevation as an immediate marker of successful coronary occlusion, while terminal myocardial tissue harvest paired with TTC-Evans blue dual staining enables precise quantitative calculation of infarct area, delivering objective histological endpoints for drug comparison. As scalable preclinical anti-ischemic drug efficacy evaluation models, these MI/R models support full-spectrum research workflows ranging from basic mechanistic pathway exploration to candidate compound pharmacodynamic screening. Researchers leverage the standardized surgical models to investigate signaling pathways governing ischemic preconditioning and reperfusion cytoprotection, quantify drug-mediated reductions in infarct size, and assess therapeutic impacts on oxidative stress, inflammatory signaling, and cardiomyocyte survival. All modeling procedures align with published cardiovascular research frameworks and peer-reviewed experimental protocols, delivering comparable, publication-quality datasets for preclinical IND-enabling studies. Ace Therapeutics has long specialized in custom cardiovascular disease animal model development, maintaining a full-service platform spanning atherosclerosis, hypertension, thrombosis, heart failure, and now refined MI/R injury systems. The launch of its standardized validated custom MI/R models fills a critical gap for partners seeking turnkey, validated preclinical anti-ischemic drug efficacy evaluation models without the resource burden of in-house surgical model optimization. Its integrated service package covers full model construction, intraoperative physiological monitoring, post-operative animal care, tissue collection, histochemical staining, and quantitative infarct analysis, streamlining end-to-end cardiovascular preclinical testing. Investigators and pharmaceutical developers focused on myocardial protection, anti-infarction, and reperfusion injury therapies can access Ace Therapeutics' complete animal models of cardiovascular disease for customized study design. Its cross-disciplinary team of cardiovascular pharmacologists, veterinary surgeons, and pathologists tailors model parameters—including ischemia duration, reperfusion timeline, and species selection—to match unique research hypotheses and drug development milestones. About Ace Therapeutics Ace Therapeutics is a leading provider of cardiovascular basic research services and custom preclinical animal model development. Its comprehensive disease model library enables translational research and drug efficacy assessment for ischemic heart disease, metabolic cardiovascular disorders, and chronic heart failure, supporting global academic institutions, biotech startups, and pharmaceutical enterprises in advancing novel cardiovascular therapeutics.
- July 23, 2026Medicine & Pharmaceuticals
Reputation House Published Sector-Wide Analysis of Digital Reputation Across Leading U.S. Pharma Companies
Reputation House has released its digital risk report for the pharmaceutical sector, a sector-wide analysis of digital reputation across 17 leading companies with a significant U.S. market presence. Each company was assessed using Risk Check, Reputation House's free AI-powered diagnostic platform, which maps how controllable a company's digital presence is across media and social channels, search results, AI-generated interpretations, and consumer trust signals. The report finds that digital reputational risk in pharma is structural rather than episodic. It is shaped less by current crises than by accumulated legal history, fragmented brand identity, and the growing influence of AI-generated content on how a brand is perceived. Across the 17 companies, the average Composite Risk Score is 33 out of 100, where a higher score indicates greater exposure. That places the sector average just above the boundary between the LOW and MEDIUM bands. Eleven companies landed in MEDIUM and six in LOW, with a high of 42 and a low of 24. "For years, pharmaceutical companies have invested in managing search results and press coverage, and those investments still matter. But a new discovery surface has emerged. When a patient, an investor, or a journalist asks an AI system about a company today, the answer often leans on decades of indexed regulatory and litigation history rather than on where the company stands now. That gap between how a company presents itself and how AI describes it is the reputational challenge of this decade, and it's one that traditional communications was never built to address. We built Risk Check so companies can finally see that problem and act on it," said Kristina Shinkareva, CEO of Reputation House. The most striking result concerns AI. Every company scored MEDIUM on AI Perception – the dimension that measures the gap between how a company positions itself and how AI systems like ChatGPT, Gemini, and Perplexity describe it. At this sample size, the metric doesn't yet differentiate between companies, so the report treats this as an early-stage, observational signal rather than a settled finding. But the pattern is clear enough to act on. AI systems draw heavily on the most authoritative and most heavily indexed sources – encyclopedias, news archives, government and litigation records — and for pharmaceutical brands that material disproportionately reflects regulatory actions, warning letters, pricing lawsuits, and historical controversies. Even companies with otherwise strong digital profiles inherit this framing. The legal matter may be long resolved; the digital signal persists. This is the central takeaway of the report. As AI becomes a primary discovery surface for patients, investors, and journalists, companies face a new category of risk that traditional PR and search-optimization frameworks were never built to measure: the gap between institutional reputation and AI-mediated perception. Alongside it, the report identifies brand-identity fragmentation – from spinoffs, name collisions, and subsidiary confusion – as a persistent, cross-channel vulnerability that AI systems tend to amplify rather than resolve. The full report is available at the official website of Reputation House . About Reputation House Reputation House is an international technology company specializing in digital risk protection. Our product combines a proprietary platform, an expert team, and an independent research division into a single solution for monitoring and controlling digital reputation risks before they become business losses. Official website: https://reputation.house About Risk Check RiskCheck is a free diagnostic platform that allows companies to assess their level of digital risk in just a few minutes and understand how stable their information environment really is. Available at: https://checkmyrisks.com Full Report direct link: https://rc.reputation.house/pharma-reputation-risk-research-2026
- July 23, 2026Medicine & Pharmaceuticals
Flavettes Celebrates Healthcare Heritage in Merdeka 2026 Campaign
Duopharma Biotech Berhad ("Duopharma Biotech" or "the Company") officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik. The launch event saw the attendance of Zuraini Abdul Ghani, Director of Package Development Division, Tourism Malaysia; Wan Amir-Jeffery Wan Abdul Majid, Group Chief Executive Officer, Duopharma Biotech; Noor Aida Jaafar, Chief Commercial Officer, Duopharma Biotech; Foo Hwei Jiek, Trading Director, Watsons Malaysia; Ekram Faiz, Director and Co-Founder, Kapten Batik; and Farhan Omar, Director and Co-Founder, Kapten Batik. Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid remarked, “At Duopharma Biotech, we’re proud that Flavettes has been trusted by generations of Malaysians to support their health and wellness, captured in our Merdeka 2026 campaign theme ‘Flavettes Setia Menemani Setiap Generasi’. Today, after more than 30 years in the market, Flavettes offers more than just immunity support. In line with Duopharma Biotech’s aim of Providing Smarter Solutions for a Healthier Life, the brand has grown to include a wider Halal-certified portfolio of health, wellness, beauty, and skincare solutions, in various formats such as effervescent, chewable and powder in sachets, to suit the different lifestyles and preferences of modern consumers looking for a more holistic approach to well-being.”
- July 22, 2026Medicine & Pharmaceuticals
PUKO Nutrition Launches Focus + Drive: A Two-Speed Nootropic for Clean Energy Now and Brain Support That Builds Over Weeks
PUKO Nutrition , a U.S. direct-to-consumer company focused on cognitive performance, today announced the nationwide launch of PUKO Focus + Drive, a daily nootropic supplement designed to support mental energy on two timelines: within the hour, and over the weeks that follow. It is the first stage of a three-part system that treats daytime focus and nighttime recovery as two halves of the same cognitive engine. The flagship pairs slow-release guarana with clinically studied phosphatidylserine at fully disclosed doses to support mental energy through the workday. Two melatonin-free night formulas carry the same system into sleep, the brain's window for recovery and long-term nutrition. Focus + Drive takes a different route. Each two-capsule serving pairs 200 mg of guarana extract, a plant caffeine source whose gradual release comes from caffeine naturally bound to tannins and fiber, with 60 mg of phosphatidylserine, a structural phospholipid of brain cell membranes that supports healthy cognitive function and brain cell communication.The guarana supports alertness and reaction time within 30 to 60 minutes, while the phosphatidylserine builds cognitive support over four to six weeks of consistent daily use.* Both doses are printed in full on the label, with no proprietary blends and no synthetic caffeine. "Most energy products sell a stronger hit. We built a base that compounds," the company said in a statement. "Guarana gives you clean mental energy this afternoon, and phosphatidylserine supports memory and attention over weeks of daily use.* Energy is the entry point. Thinking performance is the goal." The second stage of the system is sleep, and PUKO approaches it as brain infrastructure rather than a separate category. During deep, slow-wave sleep the brain naturally consolidates the day's learning into memory and clears the metabolic byproducts of a full day of thinking. That is why the CDC's finding that more than one in three U.S. adults does not get enough sleep is as much a performance problem as a health one.PUKO's two night formulas support that overnight window without synthetic melatonin. PUKO Unwind + Sleep KSM-66 combines 240 mg of magnesium glycinate chelate, 200 mg of KSM-66® ashwagandha extract standardized to 5% withanolides, and 150 mg of lemon balm extract to support evening wind-down and the body's response to everyday stress.* PUKO Deep Sleep + Recovery pairs 240 mg of magnesium glycinate chelate with Montmorency tart cherry powder, a natural source of melatonin precursors, and saffron extract to support deep, restorative sleep and long-term brain nutrition through consistent overnight recovery.* Both are non-habit forming. "Better sleep is the most underrated layer of cognitive performance," the company added. "The daytime capsule supports the hours you spend thinking. The night formulas support the hours your brain uses to consolidate what you learned and restock for tomorrow. That is why we built them as one staged system instead of separate products." The full system is available now at pukonutrition.com. ABOUT PUKO NUTRITION PUKO Nutrition is a U.S. direct-to-consumer supplement company founded in 2022. Its staged three-formula system supports daytime focus and deep, restorative sleep as the foundation of long-term cognitive performance. All formulas are non-habit forming and third-party tested, the sleep formulas contain no synthetic melatonin, and every label discloses the exact dose of every active ingredient. Learn more at https://pukonutrition.com .
- July 21, 2026Medicine & Pharmaceuticals
"Grandpa Sugar Pill" Honored at UNESCO Headquarters Centenary Commemoration of Gu Fangzhou Held in France
On July 16, the launch ceremony of the event themed A Century of Legacy, A Future of Shared Prosperity – Commemorative Event for the 100th Anniversary of the Birth of Gu Fangzhou was held at UNESCO Headquarters in Paris. Jointly organized by the China Association for Science and Technology, the National Commission of the People's Republic of China for UNESCO, and the Permanent Delegation of the People's Republic of China to UNESCO, the activity gathered more than 100 representatives from UNESCO, permanent delegations of Cambodia, Italy and other countries to UNESCO, the Institut Pasteur, the Accademia Nazionale dei Lincei, as well as top Chinese and foreign universities and public health research institutions. This international exchange platform served to celebrate the spirit of scientists, showcase the commitment and sense of duty of Chinese medical science and technology workers, and share the compelling stories of Chinese scientists with a global audience. Gu Fangzhou (1926–2019) was a distinguished Chinese virologist. He led the research and development of oral poliovirus vaccine, widely known as the "sugar pill", which protected hundreds of millions of Chinese children from poliomyelitis and earned him the affectionate title "Grandpa Sugar Pill". Under his leadership, China attained the polio-free certification in 2000. Moreover, he shared China’s mature large-scale immunization experience and low-cost vaccine technologies with developing countries, creating an exemplary model for South-South health cooperation. The launch ceremony featured keynote speeches from distinguished guests. H.E. Ms Yang Xinyu, Ambassador, Permanent Delegate of the People's Republic of China to UNESCO, attended and delivered an address. Speeches were delivered by Abou Amani, Assistant Director-General for Sciences, a.i., UNESCO; H.E. Mr Kosal Long, Ambassador Extraordinary and Plenipotentiary, Permanent Delegate of the Kingdom of Cambodia to UNESCO; Professor Maria Vittoria Cubellis from the Permanent Delegation of the Republic of Italy to UNESCO, alongside representatives of other national permanent delegations. Dr. LUO Hui, Executive Secretary for International Affairs and Strategy Research, China Association for Science and Technology, delivered a speech and officially opened the commemoration ceremony, witnessing this important moment together with all attendees. In her remarks, Luo said CAST, China's largest organization representing science and technology professionals, co-organized the commemorative events with UNESCO to highlight the significance of Gu's legacy for today's world. She said technological innovation should serve humanity, scientific achievements require sustained commitment, research should be guided by ethical principles, and human progress depends on international exchanges and mutual learning. Abou Amani stated that Gu Fangzhou’s life story can stimulate young people’s interest, curiosity and aspiration for science. UNESCO intends to deepen cooperation with CAST and other relevant institutions, with a focus on science popularization, improving public scientific literacy and science education. The two sides will jointly build exchange platforms and hold thematic exhibitions to bring science closer to the public and encourage more young people to engage in scientific careers. Yang Xinyu pointed out that humanity is currently facing shared challenges including emerging infectious diseases, climate change, biodiversity loss and technological transformation. Gu Fangzhou’s philosophy aligns closely with the core mission of UNESCO. His life experience tells us that science can realize its greatest value only through knowledge sharing, strengthened multilateral cooperation, and universal access to innovative scientific achievements. During the scientific and cultural exchange session, Mr Gu Lienan, second son of the late Dr. Gu Fangzhou, delivered remarks and recounted touching stories of his father’s lifelong dedication to polio prevention and treatment. A panel of Chinese and foreign experts held thematic academic dialogues focusing on cutting-edge immunology and vaccine development research. The speakers include: Chu Yiwei, Vice President, Chinese Society for Immunology; President, Shanghai Society for Immunology; Aleksandra Deczkowska, Research Expert, Department of Immunology and Neuroscience, Institut Pasteur (France); Wang Jin, Professor of Neurosurgery at Tsinghua University and the Washington University School of Medicine; Véronique Briquet-Laugier, PhD in Biophysics, Senior Manager of Scientific Affairs, Agence Nationale de la Recherche (ANR), France. In December 2025, the 43rd Session of the UNESCO General Conference formally approved the inclusion of the Commemorative Event for the 100th Anniversary of the Birth of Gu Fangzhou in UNESCO’s official programme for 2026–2027. Hosting this commemoration at UNESCO Headquarters stands as full recognition from the international community of Gu Fangzhou’s outstanding scientific contributions and noble humanistic spirit, as well as a key initiative to boost exchanges and mutual learning within the global public health sector. From "Grandpa Sugar Pill" Gu Fangzhou to the enduring spiritual legacy of the "People’s Scientist", the touching stories of Chinese medical science and technology workers devoting their entire lives to safeguarding human health keep spreading across the global stage.
- July 20, 2026Medicine & Pharmaceuticals
CD BioSciences Launches Custom Zebrafish Aging Model Services to Accelerate Anti-Aging and Geriatric Drug Discovery
CD BioSciences unveiled a complete portfolio of tailored zebrafish (Danio rerio) aging model development and analytical services, addressing rising global demand for robust in vivo platforms to dissect aging biology, age-related cognitive decline, and therapeutic interventions for degenerative disorders. Against a backdrop of extended human lifespans and limited understanding of long-term anti-aging therapeutic efficacy, zebrafish have emerged as a gold-standard preclinical organism. The species undergoes gradual aging that parallels human physiological and behavioral shifts, paired with mature molecular and genetic toolkits to decode cellular drivers of age-associated cognitive impairment. CD BioSciences’ newly expanded service suite integrates genetic, dietary, and pharmacological aging induction strategies, delivering flexible, reproducible model systems for academic labs and pharmaceutical drug developers alike. Leveraging Tol2 transposon insertional mutagenesis alongside CRISPR-Cas9 genome editing, CD BioSciences generates CRISPR-Cas9 transgenic zebrafish aging models with either accelerated or prolonged lifespans. Researchers can precisely modulate conserved longevity signaling axes including sirtuin pathways, insulin/IGF-1 cascades, and cellular senescence programs. Complementary transient gene modulation tools, such as Morpholino antisense oligonucleotides and in vitro transcribed capped mRNA microinjection, are also available for embryonic and adult-stage target gene silencing, enabling granular functional validation of aging-related genes. Complementing genetically modified lines, CD BioSciences engineers pharmacologically-induced and diet-induced premature senescence zebrafish to recapitulate environmentally driven aging phenotypes. For dietary induction, customized high-calorie, high-fat, or nutrient-deficient feeding regimens reliably trigger early senescence and the full spectrum of age-linked pathological traits. Pharmacological aging induction relies on well-characterized agents including rapamycin, allowing controlled onset of aged physiological states without permanent genomic alteration. This dual induction system lets clients disentangle environmental and genetic contributions to senescence, supporting mixed-factor disease modeling that mirrors the multifactorial origins of human age-related illnesses. Beyond model construction, CD BioSciences delivers end-to-end phenotypic profiling workflows. Comprehensive quantitative assays and in vivo imaging pipelines quantify age-related changes spanning physical function, cognitive performance, tissue histopathology and senescence biomarkers, tracking the progressive timeline of aging at cellular and organismal levels. The customizable platforms further support complex age-related disease modeling, combining genetic, dietary, and pharmaceutical triggers to recapitulate neurodegenerative, cardiovascular, and other late-onset pathologies for translational research. With decades of collective expertise in aquatic model organism engineering and geroscience research, CD BioSciences unifies model generation, phenotypic analysis, and translational drug testing under one integrated service pipeline. All generated zebrafish aging models and supporting analytical assays are exclusively for preclinical laboratory investigation. Researchers and pharmaceutical developers seeking custom aging model solutions can directly contact CD BioSciences’ technical support team for project consultation. About CD BioSciences CD BioSciences is a leading global supplier of tailored preclinical animal model development, molecular biology testing, and translational research services. It specializes in custom aging, disease and transgenic model systems across multiple aquatic and mammalian species, supporting target validation, mechanism exploration, and small-molecule therapeutic screening for academic, biotech, and pharmaceutical partners worldwide.
ALL NEWS
- XRPPower Launches Its Android App on Google Play, Expanding Access to AI-Powered Digital Asset Services
- $120,000 and One Million Visitors in 48 Hours for Solo Founder's Side Project Outbid.lol
- pixelgrinder Announces Second Full-Length Album “White Mask” for September 25 Release
- HAKLO Announces General Availability of Family Culture App
- IOI Wins Triple Honours For Driving Digital Transformation
- Atturra Supports Invercargill City Council Go Live With Cloud-Based TechnologyOne HR and Payroll Platform
- Ampol Deepens Support for Regional Communities Through Expanded Rural Aid Partnership
- Salter Brothers Tech Fund continues strong performance following Two Portfolio Exits
- The Anxious Uncle of the Fourth Shoplot
- The Risks They Never Saw Coming, and Why Both Lost Money Anyway
- CATL Achieves 2025 Core Operation Carbon Neutrality Target, Sets Path to 2035 Value-Chain Goal
- CATL Aviation Battery Passes Thermal Runaway Test for Adjacent Cells
- CATL and Quinbrook Build on Supernode Partnership Following Stage 2 and Stage 3 Major Milestones
- AWC and Fairmont Hotels & Resorts Unveil Fairmont Bangkok Sukhumvit, Thailand’s First Fairmont Hotel and New Luxury Lifestyle and MICE Destination
- AWC Delivers Continued Strong Growth in Q2/2026 with THB 5,502 Million in Total Revenue and THB 1,468 Million in Net Profit
- AWC Expands “AWC Riverside Journey” with THB 2.9 Billion New Luxury Destination in One of the Most Prime Locations Along the Chao Phraya River
- Munich Re Group to Acquire Cyber Insurtech At-Bay
- IJM Resells Treasury Shares as Part of its RM3 billion Value Realisation Initiative
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS